The case for & against
Bull & Bear analysis
Bearish
Invivyd, Inc. (NASDAQ: IVVD), formerly known as Adagio Therapeutics, Inc. (ADGI), is a biotechnology company focused on the advancement of therapeutic interventions, particularly in the fields of viral infections and immune response. Positioned within the larger theme of biopharmaceutical innovation, Invivyd is currently exploring the results of its VYD2311 studies, which are pivotal for understanding its approach to enhancing patient outcomes in respiratory viral infections.
Bull says
- ↑Cantor Fitzgerald and H.C. Wainwright rate Overweight/Buy with $10 PT
- ↑DECLARATION and LIBERTY trials of VYD2311 readout due soon
- ↑Market cap jumped 50% in 30 days to $237M
- ↑Recent inducement grants signal talent retention for pipeline support
- ↑High earnings yield, strong profitability and momentum suggest undervaluation
- ↑Robust balance sheet per Capri Rank insulates against volatility
Bear says
- ↓Multiple insiders sold shares, flagging internal confidence concerns
- ↓Analysts project only $4.68 stock by late 2026
- ↓High failure risk in clinical trials could trigger sharp declines
- ↓Stock could become value trap if growth misses expectations
- ↓Weak EPS revisions and sluggish sales growth weigh on sentiment
- ↓Elevated short interest and poor profitability factors add volatility